ES2196063T3 - Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales. - Google Patents

Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.

Info

Publication number
ES2196063T3
ES2196063T3 ES95919986T ES95919986T ES2196063T3 ES 2196063 T3 ES2196063 T3 ES 2196063T3 ES 95919986 T ES95919986 T ES 95919986T ES 95919986 T ES95919986 T ES 95919986T ES 2196063 T3 ES2196063 T3 ES 2196063T3
Authority
ES
Spain
Prior art keywords
hemorragies
medicines
treatment
progesterone
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919986T
Other languages
English (en)
Inventor
Kristof Chwalisz
Klaus Stockemann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2196063T3 publication Critical patent/ES2196063T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LOS ANTAGONISTAS DE PROGESTERONA COMPETITIVOS (ANTIGESTAGENOS) SON IDONEOS PARA LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE HEMORRAGIAS UTERINAS DISFUNCIONALES (METRORRAGIAS, MENORRAGIAS, HIPERMENORREAS).
ES95919986T 1995-02-02 1995-02-02 Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales. Expired - Lifetime ES2196063T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (1)

Publication Number Publication Date
ES2196063T3 true ES2196063T3 (es) 2003-12-16

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919986T Expired - Lifetime ES2196063T3 (es) 1995-02-02 1995-02-02 Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.

Country Status (20)

Country Link
US (1) US6451780B1 (es)
EP (1) EP0806952B1 (es)
JP (1) JPH10512889A (es)
KR (1) KR100370908B1 (es)
AT (1) ATE235907T1 (es)
AU (1) AU714959B2 (es)
CA (1) CA2186953C (es)
DE (1) DE59510626D1 (es)
DK (1) DK0806952T3 (es)
ES (1) ES2196063T3 (es)
FI (1) FI117850B (es)
HU (1) HU226276B1 (es)
MX (1) MX9603889A (es)
NO (1) NO964155D0 (es)
NZ (1) NZ287024A (es)
PL (1) PL316533A1 (es)
PT (1) PT806952E (es)
SK (1) SK282570B6 (es)
UA (1) UA37259C2 (es)
WO (1) WO1996023503A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001334T2 (tr) * 1997-11-14 2000-09-21 Akzo Nobel N.V. Progestojen-anti-progestojen rejimleri.
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
CO5200772A1 (es) 1999-08-31 2002-09-27 Jenapharm Gmbh And Co Kg Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
WO2005120432A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
MX385658B (es) 2016-10-07 2025-03-18 Oric Pharmaceuticals Inc Inhibidores del receptor de glucocorticoides.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
EP0806952B1 (de) 2003-04-02
FI963049L (fi) 1996-10-01
WO1996023503A1 (de) 1996-08-08
UA37259C2 (uk) 2001-05-15
HU9602668D0 (en) 1996-11-28
KR970704451A (ko) 1997-09-06
ATE235907T1 (de) 2003-04-15
PL316533A1 (en) 1997-01-20
JPH10512889A (ja) 1998-12-08
US6451780B1 (en) 2002-09-17
DK0806952T3 (da) 2003-06-16
HU226276B1 (en) 2008-07-28
KR100370908B1 (ko) 2003-04-10
CA2186953A1 (en) 1996-08-08
SK121996A3 (en) 1997-05-07
NO964155L (no) 1996-10-01
PT806952E (pt) 2003-08-29
AU714959B2 (en) 2000-01-13
CA2186953C (en) 2009-11-10
AU2561195A (en) 1996-08-21
DE59510626D1 (de) 2003-05-08
NZ287024A (en) 2001-03-30
MX9603889A (es) 1997-04-30
NO964155D0 (no) 1996-10-01
SK282570B6 (sk) 2002-10-08
EP0806952A1 (de) 1997-11-19
FI117850B (fi) 2007-03-30
FI963049A0 (fi) 1996-08-01
HUT75930A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
ES2153907T3 (es) Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
NO994850L (no) Farmakologiske midler
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
NO20020574L (no) Substituerte 1,5-dihydropyrrol-2-on derivater som er virksomme som NMDA-reseptorantagonister for behandlingen avsmertetilstanden
DK1019426T3 (da) Hidtil ukendte A1-adenosinreceptoragonister og -antagonister
BR9909486A (pt) Compostos calcilìticos
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
IT1270612B (it) Derivati eterociclo-condensatori di morfinoidi
SE9702794D0 (sv) New compounds
ES2152948T3 (es) Derivados de imidazol, triazol y tetrazol.
ES2172939T3 (es) Nuevos compuestos que son antagonistas de receptores acoplados a proteina g de 7-transmembrana (tm) de p2-purinoceptores.
ES2187783T3 (es) Derivados de indolina utiles como antagonistas del receptor 5-ht-2c.
IS2702B (is) Notkun á (11beta, 17beta)-11-(1,3-bensódíoxól-5-ýl)-17-hýdroxý-17-(1-própýnýl)-estra-4,9-díen-3-ón í meðhöndluninni á alvarlegri geðdeyfðartruflun
PE20020894A1 (es) USO DE LIGANDOS SELECTIVOS PARA ERß PARA REGULAR LA FERTILIDAD
NO904470D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater.
IT1295356B1 (it) Derivati chinolinici, procedimento per la loro preparazione e uso come antagonisti del recettore nk3
IT1296975B1 (it) Derivati chinolinici procedimento per la loro preparazione e uso come antagonisti del recettore nk3
NO912497D0 (no) Doseringsform for administrering av kalsiumantagonist.
NO891678L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.
NO890502L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etanolamin-derivater.
MX9301870A (es) Antagonistas receptores de angiotensina ii
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande